JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/20.06.25 | Real-time Bid/Ask 07:17:37 2024-07-17 am EDT | ||
| 0.16 EUR / 0.17 EUR | +26.92% |
|
| 1 month | -18.75% | ||
| 3 months | -74.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.16 | +23.08% |
| 24-07-16 | 0.13 | -13.33% |
| 24-07-15 | 0.15 | 0.00% |
| 24-07-12 | 0.15 | 0.00% |
| 24-07-11 | 0.15 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 05:34 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK6294 |
| ISIN | DE000JK62940 |
| Date issued | 2024-04-12 |
| Strike | 50 $ |
| Maturity | 2025-06-20 (339 Days) |
| Parity | 10 : 1 |
| Emission price | 0.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.53 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.01 € |
| Spread % | 5.88% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
51.69
USD
Spread / Average Target
+25.47%
- Stock Market
- Warrants
- Warrant
